According to the business analysis report titled ‘United States Non-Invasive Prenatal Testing Market 2019 – 2026’, available with MarketStudyReport, the United States non-invasive prenatal testing market is expected to record CAGR of more than 13% through 2026.
 

The United States non-invasive prenatal testing market is expected to be driven by the development of superior testing products, a greater inclination towards non-invasive methods as opposed to invasive counterparts, and enactment of ACOG guidelines that emphasize on NIPT procedures for all pregnancies regardless of the risk involved.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/2132979/
 

Apart from growth drivers and opportunities, the research report contains details about current and upcoming challenges in the business sphere, while also divulging solutions for the same. It also offers an up-to-date analysis of market size, growth rate, volume of sales and revenue shares over the forecast period.
 

Furthermore, the research literature sheds light on other important aspects such as licensing agreements, reimbursement patterns, regulatory frameworks, distribution channels, major partnership and collaboration and partnership deals, mergers acquisitions, and capital investments which to aid stakeholders to make beneficial decisions.
 

Speaking of the competitive landscape, the United States non-invasive prenatal testing market report conducts a deep-dive survey on the key players. It analyses these companies based on parameters such as business overview, recent developments with respect to the product portfolio, production volume, consumption value, and other financials.
 

The reputed companies that play an important role in the industry are Myriad Genetics, Illumina, Inc., Centogene, Natera Inc. Quest Diagnostics, Invitae Corporation, GenPath Diagnostics, Otogenetics Corporation, Progenity, Inc., Agilent Technologies, Inc., Ariosa Diagnostics (Roche), and Integrated Diagnostics (LabCorp).